Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vatalanib + oxaliplatin + 5-fluorouracil + leucovorin
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination consists of **vatalanib**, a small molecule inhibitor of several receptor tyrosine kinases involved in angiogenesis, and the established chemotherapy regimen **oxaliplatin + 5-fluorouracil + leucovorin** (known as FOLFOX). Vatalanib targets all known vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor beta (PDGFR-β), and c-Kit; at higher concentrations, it may also inhibit epidermal growth factor receptor (EGFR) and fibroblast growth factor receptors. The chemotherapy agents include oxaliplatin (a platinum-based DNA crosslinker), 5-fluorouracil (a pyrimidine analog inhibitor of thymidylate synthase), and leucovorin (which enhances 5-FU’s activity). This combination is primarily studied for the treatment of **metastatic colorectal cancer** and other advanced solid tumors, with trials demonstrating improved progression-free survival in certain subgroups, such as patients with high LDH[1][2][4][5].
- Other names
- vatalanib + oxaliplatin + 5-fluorouracil + leucovorinFOLFOX + vatalanib
02
Targets
TS (Thymidylate synthase)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR2 (Vascular endothelial growth factor receptor 2)DNAVEGFR-1 (Vascular endothelial growth factor receptor 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on vatalanib + oxaliplatin + 5-fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vatalanib + oxaliplatin + 5-fluorouracil + leucovorin.